IMFINZI® plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer 17h
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials 18h
ETCAMAH® in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer 04 September
